4DMedical Secures US$10m Philips Contract to Distribute CT:VQ™ in US and Canada
4DMedical has expanded its partnership with Philips, securing a US$10 million order commitment to distribute its CT – VQ™ lung imaging technology across North America, aiming to transform pulmonary diagnostics.
- Philips commits to US$10 million minimum orders over two years for CT – VQ™
- CT, VQ™ added to Philips’ North American product catalogue with dedicated sales teams
- Technology offers non-contrast, radiotracer-free lung ventilation and perfusion imaging
- Targets displacement of traditional nuclear VQ scans in US and Canada
- Commercial launch announced at Radiological Society of North America 2025
A Major Commercial Milestone
4DMedical Limited (ASX – 4DX) has taken a significant step forward in commercialising its groundbreaking lung imaging technology, CT – VQ™, by expanding its distribution agreement with global healthcare giant Koninklijke Philips NV. The deal commits Philips to a minimum of approximately US$10 million in orders over the next two years, marking a substantial validation of 4DMedical’s technology and opening the door to rapid adoption across the United States and Canada.
This partnership leverages Philips’ extensive commercial infrastructure and customer relationships, enabling CT – VQ™ to reach a broad spectrum of healthcare providers. Philips will deploy dedicated sales and clinical specialists focused on CT – VQ™, supported by joint marketing and co-branding campaigns, with the official commercial launch unveiled at the prestigious Radiological Society of North America (RSNA) annual meeting in 2025.
Transforming Pulmonary Imaging
CT – VQ™ represents a paradigm shift in ventilation-perfusion imaging by extracting detailed lung function data from routine, non-contrast CT scans. Unlike traditional nuclear VQ scans, which require radioactive tracers, CT – VQ™ eliminates the need for radiotracers and contrast agents, simplifying logistics and regulatory hurdles while improving patient access and comfort.
The technology’s ability to integrate seamlessly with existing CT scanners, of which there are approximately 14,500 installed across the US healthcare system, means it can democratize access to advanced pulmonary diagnostics, including in rural and community hospitals that may lack nuclear medicine infrastructure. This broad accessibility, combined with superior image resolution and precise quantification, positions CT – VQ™ to potentially displace all nuclear VQ scans over time.
Market Potential and Strategic Outlook
The US market alone performs over one million nuclear VQ scans annually, with an average reimbursement of around US$1,150 per scan, representing an addressable market exceeding US$1.1 billion. Globally, this figure rises to over US$2.6 billion. 4DMedical’s management is confident that CT – VQ™’s clinical and logistical advantages will not only capture significant market share but also expand the overall demand for ventilation-perfusion imaging beyond traditional indications.
CEO Andreas Fouras highlighted the deal as a "major commercial inflection point," emphasizing Philips’ commitment as a strong endorsement of CT – VQ™’s transformative potential. The collaboration is expected to accelerate adoption and scale revenue, supported by Philips’ leadership and resources.
Investors and analysts will be watching closely as 4DMedical prepares to host an investor webinar to provide further insights into the Philips contract and its implications for the company’s growth trajectory.
Bottom Line?
With Philips’ backing, 4DMedical is poised to redefine lung imaging and capture a multi-billion-dollar market opportunity.
Questions in the middle?
- How quickly will Philips’ sales efforts translate into widespread clinical adoption of CT, VQ™?
- What competitive responses might emerge from established nuclear VQ scan providers?
- How will reimbursement policies evolve to support CT – VQ™ in different healthcare systems?
